Literature DB >> 8556063

Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration.

H Shimizu1, K Ohtani, N Sato, T Nagamine, M Mori.   

Abstract

Systemic administration of human interferon-alpha stimulates the pituitary-adrenal axis in men, but the exact mechanism still remains to be established. The present study was undertaken to examine the hypothesis that interferon-alpha may alter the circulating concentrations of the cytokines which involve the activation of the pituitary-adrenal axis. Eleven patients with chronically active hepatitis C were treated with human lymphoblastoid interferon-alpha (IFN: 6 x 10(6) IU/day) and changes in plasma adrenocorticotropin (ACTH), serum cortisol and cytokine concentrations were observed on both the first and second days of the treatment. Subcutaneous administration of IFN significantly increased plasma ACTH and serum cortisol concentrations by 3 h after the injection. Serum interleukin-6 (IL-6) increased with the increase in circulating ACTH and cortisol. There was a significant correlation between serum cortisol and IL-6 concentrations at 3 h. In contrast, an increase in serum interleukin-1 beta was only observed in one case. On the second day of IFN treatment, simultaneous administration of 25 mg diclofenac sodium eliminated the IFN effects on circulating ACTH, cortisol and IL-6 concentrations. The present studies demonstrated that circulating IL-6 increases after systemic IFN administration, resulting in activation of the pituitary-adrenal axis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8556063     DOI: 10.1507/endocrj.42.551

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  9 in total

Review 1.  Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.

Authors:  R E Kast
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.

Authors:  Jennifer C Felger; Oyetunde Alagbe; Fang Hu; Deborah Mook; Amanda A Freeman; Mar M Sanchez; Ned H Kalin; Emiliangelo Ratti; Charles B Nemeroff; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

Review 3.  Potential role of type I interferons in the treatment of pituitary adenomas.

Authors:  Giovanni Vitale; Michele Caraglia; Peter M van Koetsveld; Paola Maroni; Monica Marra; Annamaria Colao; Steven W J Lamberts; Francesco Cavagnini; Leo J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-06       Impact factor: 6.514

Review 4.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

5.  Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality.

Authors:  Aric A Prather; Mordechai Rabinovitz; Bruce G Pollock; Francis E Lotrich
Journal:  Brain Behav Immun       Date:  2009-07-15       Impact factor: 7.217

6.  Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior.

Authors:  C L Raison; A S Borisov; B J Woolwine; Breanne Massung; G Vogt; A H Miller
Journal:  Mol Psychiatry       Date:  2008-06-03       Impact factor: 15.992

Review 7.  Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder.

Authors:  Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2009-01       Impact factor: 6.186

8.  Gene expression biomarkers of response to citalopram treatment in major depressive disorder.

Authors:  F Mamdani; M T Berlim; M-M Beaulieu; A Labbe; C Merette; G Turecki
Journal:  Transl Psychiatry       Date:  2011-06-21       Impact factor: 6.222

9.  Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy.

Authors:  Joerg F Schlaak; Martin Trippler; Carolina Hoyo-Becerra; Yesim Erim; Bernhard Kis; Bo Wang; Norbert Scherbaum; Guido Gerken
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.